Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (211-220 of 302) with videos related to

Pageof 31
Sort By:
Physical Biology|December 1, 2012
Genomic analysis and selected molecular pathways in rare cancersStephen V Liu, Elizabeth Lenkiewicz, Lisa Evers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreasR K Ramanathan, D Goldstein, R L Korn, et al.
Journal of Clinical Pharmacology|January 15, 2011
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Pancreas|June 17, 2020
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic CancerDavid Goldstein, Daniel D Von Hoff, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan, Douglas M Potter, Chandra P Belani, et al.
The Oncologist|January 14, 2015
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerJosep Tabernero, E Gabriela Chiorean, Jeffrey R Infante, et al.
International Journal of Nanomedicine|November 1, 2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Seminars in Oncology|October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow, Timothy W Synold, David Gandara, et al.
Future Oncology (London, England)|February 21, 2018
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinomaThomas T DeLeon, Daniel H Ahn, James M Bogenberger, et al.
Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.
Pageof 31

Showing results (211-220 of 302) with videos related to

Sort By:
Pageof 31
Physical Biology|December 1, 2012
Genomic analysis and selected molecular pathways in rare cancersStephen V Liu, Elizabeth Lenkiewicz, Lisa Evers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreasR K Ramanathan, D Goldstein, R L Korn, et al.
Journal of Clinical Pharmacology|January 15, 2011
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Pancreas|June 17, 2020
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic CancerDavid Goldstein, Daniel D Von Hoff, E Gabriela Chiorean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan, Douglas M Potter, Chandra P Belani, et al.
The Oncologist|January 14, 2015
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerJosep Tabernero, E Gabriela Chiorean, Jeffrey R Infante, et al.
International Journal of Nanomedicine|November 1, 2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsHuali Wu, Ramesh K Ramanathan, Beth A Zamboni, et al.
Seminars in Oncology|October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow, Timothy W Synold, David Gandara, et al.
Future Oncology (London, England)|February 21, 2018
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinomaThomas T DeLeon, Daniel H Ahn, James M Bogenberger, et al.
Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.
Pageof 31